sulfaphenazole has been researched along with fluconazole in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Ekins, S; Harwood, HJ; Hoover, DJ; Lawton, MP; Mankowski, DC; Treadway, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cheng, M; Hao, C; Liu, C; Su, X; Sun, B; Wei, P; Zhang, X; Zhao, D; Zhao, L; Zhao, S | 1 |
Cheng, M; Hao, C; Liu, C; Su, X; Wei, P; Wu, M; Zhang, X; Zhao, D; Zhao, L; Zhao, S | 1 |
Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
Cheng, M; Hao, C; Jiang, X; Su, X; Wei, P; Wu, M; Zhang, X; Zhao, D; Zhao, L; Zhao, S | 1 |
Cheng, M; Cui, H; Jiang, H; Li, S; Liu, L; Su, X; Sun, Y; Wu, T; Yin, W; Zhang, Y; Zhao, D; Zhao, L; Zheng, Y | 1 |
Hutzler, JM; Locuson, CW; Tracy, TS | 1 |
Korhonen, T; Laine, K; Pelkonen, O; Tolonen, A; Turpeinen, M | 1 |
Pickova, J; Vestergren, AS; Zamaratskaia, G; Zlabek, V | 1 |
12 other study(ies) available for sulfaphenazole and fluconazole
Article | Year |
---|---|
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
Topics: Amides; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Oxidoreductases; Quantitative Structure-Activity Relationship; Sterol 14-Demethylase | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
Topics: Antifungal Agents; Biphenyl Compounds; Candida albicans; Cryptococcus neoformans; Dose-Response Relationship, Drug; Drug Discovery; Imidazoles; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
Topics: Antifungal Agents; Aspergillus fumigatus; Candida albicans; Cryptococcus neoformans; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; Hydrocarbons, Aromatic; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2017 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
Topics: Antifungal Agents; Aspergillus fumigatus; Binding Sites; Candida albicans; Catalytic Domain; Cryptococcus neoformans; Drug Design; Drug Resistance, Fungal; Drug Stability; Fluconazole; Fungal Proteins; Gas Chromatography-Mass Spectrometry; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Isoforms; Sterol 14-Demethylase; Sterols; Structure-Activity Relationship; Triazoles | 2018 |
Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
Topics: Antifungal Agents; Candida albicans; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Fungal; Fluconazole; Fungicides, Industrial; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thiophenes | 2021 |
Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.
Topics: Aniline Compounds; Aryl Hydrocarbon Hydroxylases; Benzodioxoles; Binding Sites; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fluconazole; Heme; Humans; Imidazoles; Itraconazole; Kinetics; Ligands; Light; Models, Chemical; Molecular Structure; NADP; Nonlinear Dynamics; Protein Binding; Pyrimidines; Recombinant Proteins; Reference Standards; Regression Analysis; Spectrum Analysis; Sulfaphenazole; Triazoles | 2007 |
Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluconazole; Humans; Hydroxylation; Ketoconazole; Lynestrenol; Microsomes, Liver; Norethindrone; Sulfaphenazole | 2008 |
Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.).
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diclofenac; Dioxoles; Ellipticines; Fish Proteins; Fluconazole; Hydroxylation; Ketoconazole; Kinetics; Lignans; Microsomes, Liver; Oxazines; Salmo salar; Sulfaphenazole; Tolbutamide | 2012 |